Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 7/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2824321 | 0.82 | ALDH1A1 (0.47) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL9515062 | 0.82 | ALDH1A1 (0.47) | ALDH1A1ATMTSHRHPGDACHE | |
| SCHEMBL27623516 | 0.82 | ALDH1A1 (0.50) | ALDH1A1ATMTSHRHPGDACHE | |
| SCHEMBL29106724 | 0.81 | ALDH1A1 (0.54) | ALDH1A1ATMTSHRHPGDACHE | |
| SCHEMBL1415812 | 0.81 | ALDH1A1 (0.54) | ALDH1A1ATMTSHRHPGDACHE | |
| SCHEMBL2823450 | 0.81 | ALDH1A1 (0.45) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL6658726 | 0.81 | TSHR (0.50) | ALDH1A1ATMTSHRHPGDHCAR2 | |
| SCHEMBL114311 | 0.79 | ALDH1A1 (0.42) | ALDH1A1TSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4990675 | 0.78 | ALDH1A1 (0.61) | ALDH1A1ATMTSHRHPGDACHE | |
| SCHEMBL28787473 | 0.78 | ALDH1A1 (0.67) | ALDH1A1ATMTSHRHPGDACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2226322-B1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8927588-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8536197-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-17 | — | — | US | disclosed |
| CN-101959882-B | Imidazole carbonyl compound | DAIICHI SANKYO CO LTD | 2013-09-11 | — | — | CN | disclosed |
| CN-101959882-A | Imidazole carbonyl compound | DAIICHI SANKYO CO LTD | 2011-01-26 | — | — | CN | disclosed |
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226322-A1 | IMIDAZOLE CARBONYL COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | ALDH1A1 3596/4885ATM 580/4885TSHR 4153/4885 |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | ALDH1A1 1220/4885ATM 1655/4885TSHR 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.